Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 11Unknown 3Terminated 3Recruiting 2Suspended 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 20Thoracic 15Breast 12Head & Neck 9Other solid neoplasm 4Gynecologic 4Genitourinary 4Sarcoma 2Other hematologic neoplasm 2CNS 2Tumor-Agnostic 1Lymphoid 1Dermatologic 1

Conditions

Skin Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 72Nivolumab 49Ipilimumab 29Specimen Handling 15Magnetic Resonance Spectroscopy 15trametinib 14Biopsy 13dabrafenib 11cemiplimab 11avelumab 11binimetinib 10Radiotherapy 10Cyclophosphamide 10CTLA-4 Antigen 9fludarabine 7encorafenib 7atezolizumab 7Radiosurgery 7Immunoglobulin G 7Disulfides 7Cisplatin 7lenvatinib 6durvalumab 6Paclitaxel 6Carboplatin 6tislelizumab 5relatlimab 5fludarabine phosphate 5dostarlimab 5Pemetrexed 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Drug Therapy × Dermatologic × Clear all
NCT05704985 2025-05-29

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

DEKA Biosciences

Phase 1 Active not recruiting
39 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasms, Pancreatic Neoplasms, Skin Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡